NO20074052L - Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere - Google Patents

Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Info

Publication number
NO20074052L
NO20074052L NO20074052A NO20074052A NO20074052L NO 20074052 L NO20074052 L NO 20074052L NO 20074052 A NO20074052 A NO 20074052A NO 20074052 A NO20074052 A NO 20074052A NO 20074052 L NO20074052 L NO 20074052L
Authority
NO
Norway
Prior art keywords
processes
preparing pyrazole
pyrimidine
pyrimidine ethers
ethers
Prior art date
Application number
NO20074052A
Other languages
English (en)
Norwegian (no)
Inventor
Tawfik Gharbaoui
Dipanjan Sengupta
Edward A Lally
Naomi S Kato
Marlon Carlos
Natalie Rodriguez
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20074052L publication Critical patent/NO20074052L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20074052A 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere NO20074052L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64371205P 2005-01-13 2005-01-13
PCT/US2006/001020 WO2006076455A2 (en) 2005-01-13 2006-01-12 Processes for preparing pyrazolo[3,4-d]pyrimidine ethers

Publications (1)

Publication Number Publication Date
NO20074052L true NO20074052L (no) 2007-09-12

Family

ID=36463499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074052A NO20074052L (no) 2005-01-13 2007-08-06 Prosesser for a fremstille pyrazol[3,4-D]pyrimidinetere

Country Status (22)

Country Link
US (1) US7425630B2 (es)
EP (1) EP1838713A2 (es)
JP (1) JP2008526975A (es)
KR (1) KR20070114126A (es)
CN (1) CN101142216A (es)
AR (1) AR052557A1 (es)
AU (1) AU2006204940A1 (es)
BR (1) BRPI0606115A2 (es)
CA (1) CA2593345A1 (es)
CR (1) CR9224A (es)
DO (1) DOP2006000009A (es)
EA (1) EA013968B1 (es)
GT (1) GT200600011A (es)
HN (1) HN2006001493A (es)
IL (1) IL184365A0 (es)
MX (1) MX2007008381A (es)
NO (1) NO20074052L (es)
PA (1) PA8659701A1 (es)
PE (1) PE20061118A1 (es)
TW (1) TW200637865A (es)
WO (1) WO2006076455A2 (es)
ZA (1) ZA200705279B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
KR20060056944A (ko) * 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
GEP20135907B (en) * 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
JP6567276B2 (ja) 2014-05-13 2019-08-28 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、および電子機器
BR112017012007B1 (pt) * 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP2019122134A (ja) 2018-01-04 2019-07-22 Ntn株式会社 スイッチング電源の力率改善用pwm制御装置
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
KR20240024842A (ko) * 2021-06-23 2024-02-26 에프. 호프만-라 로슈 아게 Nlrp3 억제제의 제조 공정

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003174A1 (fr) 1980-04-28 1981-11-12 Teijin Ltd Derives de thiazolo (3,2-a) pyrimidine, leur procede de preparation, et medicaments les contenant
EP0053678A1 (de) * 1980-12-05 1982-06-16 BASF Aktiengesellschaft 5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP4022271B2 (ja) * 1995-10-31 2007-12-12 富士フイルム株式会社 ピラゾリルアゾフエノール色素
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
JP2005536517A (ja) * 2002-07-23 2005-12-02 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
KR20060056944A (ko) * 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1838713A2 (en) 2007-10-03
WO2006076455A2 (en) 2006-07-20
PE20061118A1 (es) 2006-10-13
KR20070114126A (ko) 2007-11-29
ZA200705279B (en) 2008-11-26
WO2006076455A3 (en) 2006-12-07
AU2006204940A1 (en) 2006-07-20
WO2006076455A8 (en) 2006-11-02
CN101142216A (zh) 2008-03-12
DOP2006000009A (es) 2006-08-15
PA8659701A1 (es) 2006-09-08
JP2008526975A (ja) 2008-07-24
BRPI0606115A2 (pt) 2009-06-02
GT200600011A (es) 2006-08-10
CA2593345A1 (en) 2006-07-20
EA013968B1 (ru) 2010-08-30
CR9224A (es) 2007-10-23
IL184365A0 (en) 2007-10-31
US7425630B2 (en) 2008-09-16
MX2007008381A (es) 2007-09-07
TW200637865A (en) 2006-11-01
US20060154940A1 (en) 2006-07-13
AR052557A1 (es) 2007-03-21
EA200701500A1 (ru) 2007-12-28
HN2006001493A (es) 2010-08-19

Similar Documents

Publication Publication Date Title
TW200637865A (en) Processes for preparing pyrazolo[3,4-d]pyrimidine ethers
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
MX2007007174A (es) Derivados de cicloalquilamina.
TW200637845A (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2004076413A3 (en) Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
WO2005086860A3 (en) Methods for generating insulin-producing cells
TW200610528A (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2007109211A8 (en) 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses
NO20074872L (no) Pyrazoler
TW200637844A (en) Processes for preparing aromatic ethers
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
NO20080372L (no) Pyrazolderivater som teraputiske midler
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
GB0508318D0 (en) Organic compounds
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
UA87026C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛО[3, 4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
NZ593021A (en) Method of preparing deoxyribofuranose compounds
AU2003290418A1 (en) Novel molecules to develop drug for the treatment of osteoporosis
WO2007009704A3 (en) Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application